A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

← catalyst calendar

NCT05506943 · readout in 104 d

Sponsored by Compass Therapeutics (industry) · CMPX — their whole pipeline →.

Phase

Phase 2/3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Single · Treatment

Enrollment

168actual

Sites

Country

United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-01-09

actual

When the study began enrolling

Primary completion

2026-12-01

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-12-01

estimated

The whole study's end, after follow-up

First posted

2022-08-18

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-07

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Biliary Tract Cancer
Cholangiocarcinoma
Gall Bladder Cancer
Ampullary Cancer

Interventions

Drug: CTX-009
Drug: Paclitaxel

Primary outcome

what the primary-completion date above is the date OF

Best Overall Response

measured From randomization to treatment discontinuation for any reason, average 6 months

Publications

PMID 38861293 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · CMPX's whole pipeline · Catalyst calendar · Every registered study · What changed